AU2001255013A1 - Combination of growth hormone secretagogues and antidepressants - Google Patents

Combination of growth hormone secretagogues and antidepressants

Info

Publication number
AU2001255013A1
AU2001255013A1 AU2001255013A AU5501301A AU2001255013A1 AU 2001255013 A1 AU2001255013 A1 AU 2001255013A1 AU 2001255013 A AU2001255013 A AU 2001255013A AU 5501301 A AU5501301 A AU 5501301A AU 2001255013 A1 AU2001255013 A1 AU 2001255013A1
Authority
AU
Australia
Prior art keywords
antidepressants
combination
growth hormone
hormone secretagogues
secretagogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255013A
Other languages
English (en)
Inventor
Frank Robert Busch
Willard Mckowan Welch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2001255013A1 publication Critical patent/AU2001255013A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AU2001255013A 2000-05-25 2001-05-10 Combination of growth hormone secretagogues and antidepressants Abandoned AU2001255013A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20701700P 2000-05-25 2000-05-25
US60207017 2000-05-25
PCT/IB2001/000815 WO2001089570A2 (en) 2000-05-25 2001-05-10 Combination of growth hormone secretagogues and antidepressants

Publications (1)

Publication Number Publication Date
AU2001255013A1 true AU2001255013A1 (en) 2001-12-03

Family

ID=22768871

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255013A Abandoned AU2001255013A1 (en) 2000-05-25 2001-05-10 Combination of growth hormone secretagogues and antidepressants

Country Status (17)

Country Link
US (1) US20020002137A1 (es)
EP (1) EP1284753A2 (es)
JP (1) JP2003534294A (es)
AR (1) AR028620A1 (es)
AU (1) AU2001255013A1 (es)
BR (1) BR0111002A (es)
CA (1) CA2408036A1 (es)
DO (1) DOP2001000154A (es)
EC (1) ECSP014082A (es)
GT (1) GT200100089A (es)
MX (1) MXPA02011554A (es)
PA (1) PA8517701A1 (es)
PE (1) PE20011262A1 (es)
SV (1) SV2001000465A (es)
TN (1) TNSN01076A1 (es)
UY (1) UY26731A1 (es)
WO (1) WO2001089570A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005306839A (ja) * 2003-08-29 2005-11-04 Takeda Chem Ind Ltd 二環性ピペラジン化合物およびその用途
US7795267B2 (en) 2003-08-29 2010-09-14 Takeda Pharmaceutical Company Limited Bicyclic piperazine compound having TGR23 antagonistic activity
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
EP2644618B1 (en) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
US8822498B2 (en) 2007-09-13 2014-09-02 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов
CN116724038A (zh) 2020-10-21 2023-09-08 安力高医药股份有限公司 双环化合物
US11957683B2 (en) 2021-06-18 2024-04-16 Aligos Therapeutics, Inc. Bicyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
ES2283055T3 (es) * 1997-06-25 2007-10-16 Pfizer Inc. Derivados dipeptidos como secretagogos de la hormona de crecimiento.

Also Published As

Publication number Publication date
WO2001089570A2 (en) 2001-11-29
PE20011262A1 (es) 2001-12-11
SV2001000465A (es) 2001-07-03
CA2408036A1 (en) 2001-11-29
BR0111002A (pt) 2003-04-15
EP1284753A2 (en) 2003-02-26
AR028620A1 (es) 2003-05-14
UY26731A1 (es) 2001-12-28
GT200100089A (es) 2002-01-11
DOP2001000154A (es) 2002-05-15
ECSP014082A (es) 2002-04-23
PA8517701A1 (es) 2002-12-30
US20020002137A1 (en) 2002-01-03
MXPA02011554A (es) 2003-04-25
WO2001089570A3 (en) 2002-06-20
TNSN01076A1 (fr) 2005-11-10
JP2003534294A (ja) 2003-11-18

Similar Documents

Publication Publication Date Title
AU2001229712A1 (en) Reduction of hair growth
AU2001293178A1 (en) Dental implant system and additional methods of attachment
EP1291377B8 (en) Silicone compound and cosmetic preparation
AU2001294876A1 (en) Direct growth of nanotubes, and their use in nanotweezers
AU2001229363A1 (en) Antisense modulation of caspase 3 expression
ZA986822B (en) Reduction of hair growth
AU2001253411A1 (en) Medical dressing assembly and associated method of using the same
AU7907300A (en) Novel combination of loteprednol and antihistamines
AU2001281762A1 (en) Fabrication and application of nano-manipulators with induced growth
IL137491A0 (en) Combination preparation of oestrogen and antioestrogen
AU6606601A (en) Growth hormone secretagogues
AU2001287023A1 (en) Plasma-derived-fibrin-based matrices and tissue
HUP0103072A3 (en) Use of growth hormone secretagogues
AU2001255013A1 (en) Combination of growth hormone secretagogues and antidepressants
AU6723401A (en) Antimicrobial peptides and methods of use thereof
AU2001289068A1 (en) Antisense modulation of caspase 2 expression
AU2001227848A1 (en) Antisense modulation of caspase 8 expression
EP1086215A4 (en) PREPARATION AND USE OF HIGHER VACCINES
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU7410900A (en) Alginate preparation and use of the same
AU2001277696A1 (en) Novel physiologically active peptide and use thereof
PL353487A1 (en) Novel combination of loteprednol and beta2
AU2002230129A1 (en) Novel physiologically active peptide and use thereof
AUPQ760400A0 (en) Herbical formulations and methods of use thereof
AU2001272421A1 (en) Full length human hcn1 ih channel subunit and variants